4991W93, a potent blocker of neurogenic plasma protein extravasation, inhibits trigeminal neurons at 5-hydroxytryptamine (5-HT1B/1D) agonist doses

@article{Storer20014991W93AP,
  title={4991W93, a potent blocker of neurogenic plasma protein extravasation, inhibits trigeminal neurons at 5-hydroxytryptamine (5-HT1B/1D) agonist doses},
  author={R. Storer and S. Akerman and H. Connor and P. Goadsby},
  journal={Neuropharmacology},
  year={2001},
  volume={40},
  pages={911-917}
}
Triptans share the pharmacological profile of being 5-hydroxytryptamine (5-HT1B/1D) agonists and having potent anti-migraine activity. The conformationally restricted zolmitriptan analogue 4991W93 was developed as a potent, and at low doses, specific, non-vasconstrictor inhibitor of neurogenic dural plasma protein extravasation. Here, we sought to study the effect of 4991W93 at plasma protein extravasation blocking and at 5-HT(1B/1D) agonist doses. Nociceptive cells with firing latencies… Expand
Activation of 5‐HT1B/1D receptor in the periaqueductal gray inhibits nociception
TLDR
The results suggest that 5‐HT1B/1D receptor activation in the vlPAG activates descending pain‐modulating pathways that inhibit dural, but not facial and corneal nociceptive input, suggesting that brain loci other than the trigeminal nucleus may play a role in the clinical action of triptans. Expand
The antimigraine 5‐HT1B/1D receptor agonists, sumatriptan, zolmitriptan and dihydroergotamine, attenuate pain‐related behaviour in a rat model of trigeminal neuropathic pain
TLDR
The rationale for exploring the clinical efficacy of brain penetrant 5‐HT1B/1D receptor agonists as analgesics to reduce certain types of trigeminal neuropathic pain in humans is supported. Expand
Evidence for serotonin (5-HT)1B, 5-HT1D and 5-HT1F receptor inhibitory effects on trigeminal neurons with craniovascular input
TLDR
5-HT(1B) receptor-mediated inhibition is the most potent of the three in terms of inhibition of trigeminovascular nociceptive traffic. Expand
Adenosine A1 receptor agonists inhibit trigeminovascular nociceptive transmission.
TLDR
In this model of trigeminovascular nociception, adenosine A1 receptor activation leads to neuronal inhibition without concomitant vasoconstriction, suggesting a novel avenue for the treatment of migraine and cluster headache. Expand
Calcitonin gene‐related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat
TLDR
The data suggest that there are non‐presynaptic C GRP receptors in the trigeminocervical complex that can be inhibited by CGRP receptor blockade and that a CgrP receptor antagonist would be effective in the acute treatment of migraine and cluster headache. Expand
Topiramate Inhibits Trigeminovascular Neurons in the Cat
TLDR
Inhibition of the trigeminocervical complex directly, or neurons that modulate sensory input, are plausible mechanisms for the action of preventives in migraine. Expand
Calcium channels modulate nociceptive transmission in the trigeminal nucleus of the cat
TLDR
High threshold VDCCs, including P/Q-, L- and N-type VD CCs, can therefore modulate nociceptive transmission in the trigeminocervical complex in vivo and result in significant reductions in post-synaptic action potential generation in response to l-glutamate. Expand
Predictive validity of endpoints used in electrophysiological modelling of migraine in the trigeminovascular system
TLDR
Findings do not support the view that electrically evoked responses are useful for the measurement of trigeminal sensitization, and it is proposed however, that inhibition of enhanced firing evoked by inflammatory mediators as an endpoint have higher predictive validity regarding the clinical effectiveness of compounds. Expand
Inhibitory effect of high-frequency greater occipital nerve electrical stimulation on trigeminovascular nociceptive processing in rats
TLDR
The GON stimulation-induced inhibition of trigeminovascular nociceptive processing at the level of STN has been demonstrated for the first time. Expand
Acute Treatments: Some Blind Alleys
  • N. Ramadan
  • Medicine
  • Current medical research and opinion
  • 2001
TLDR
In this chapter, blind alleys in anti-migraine development are discussed and some of the promising targets failed to demonstrate clinical efficacy, while others were stopped for preclinical toxicity. Expand
...
1
2
...

References

SHOWING 1-10 OF 38 REFERENCES
Differential effects of low dose CP122,288 and eletriptan on Fos expression due to stimulation of the superior sagittal sinus in cat☆
TLDR
The data suggest that activation of the 5HT(1B/1D) receptor is important for the clinical action of this class of compounds and is consistent with the fact the CP122,288 is ineffective in the treatment of the acute attack of migraine. Expand
Inhibition of trigeminal neurones after intravenous administration of naratriptan through an action at 5‐hydroxy‐tryptamine (5‐HT1B/1D) receptors
TLDR
It is established that naratriptan acts on central trigeminal neurones since sagittal sinus stimulation activates axons within the tentorial nerve and there are no inhibitory effects mediated within the trigemINAL ganglion. Expand
Pre-clinical pharmacology of zolmitriptan (Zomig™; formerly 311C90), a centrally and peripherally acting 5HT1B/1D agonist for migraine
  • G. Martin
  • Medicine
  • Cephalalgia : an international journal of headache
  • 1997
TLDR
A novel preclinical profile not only distinguishes zolmitriptan from sumatriptan, but raises intriguing questions about the clinical relevance of a dual action. Expand
Inhibition of trigeminal neurons by intravenous administration of the serotonin (5HT)1B/D receptor agonist zolmitriptan (311C90): are brain stem sites therapeutic target in migraine ?
TLDR
It is demonstrated that systemically administered zolmitriptan can inhibit evoked trigeminovascular activity within the trigeminal nucleus, which may play a role in the anti‐migraine actions of this compound and offers the prospect of a third pathophysiologically consistent target site for anti‐Migraine drug effects. Expand
The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater
TLDR
The results demonstrate an important action of GR43175 on neurogenic mechanisms in dural blood vessels and suggest that drugs useful in the treatment of acute vascular headaches may share a similar mechanism of action. Expand
Blockade of calcitonin gene-related peptide release after superior sagittal sinus stimulation in cat: a comparison of avitriptan and CP122,288
TLDR
It is demonstrated that the potent inhibitor of PPE, CP122, 288, which has been shown in clinical trials to be ineffective in treating acute migraine attacks, had no effect on CGRP release, whereas the effective anti-migraine drug and relatively impotent inhibitor ofPPE, avitriptan, blocked C GRP release. Expand
Microiontophoretic application of serotonin (5HT)1B/1D agonists inhibits trigeminal cell firing in the cat.
TLDR
These data demonstrate that the second order trigeminal nucleus synapse in the brainstem and upper cervical cord is the most likely site of action for brain penetrant anti-migraine drugs of the 5HT1B/1D class. Expand
Differential Distribution of 5Ht1D-and 5HT1B-Immunoreactivity within the Human Trigemino-Cerebrovascular System: Implications for the Discovery of New Antimigraine Drugs
TLDR
A differential distribution of these receptor subtypes within the human trigemino-cerebrovascular system is demonstrated using 5HT1D- and5HT1B-receptor-specific antibodies and has important implications for the design of new antimigraine drugs. Expand
Receptor specificity and trigemino‐vascular inhibitory actions of a novel 5‐HT1B/1D receptor partial agonist, 311C90 (zolmitriptan)
TLDR
The receptor specificity of the drug and its actions on trigeminal‐evoked plasma protein extravasation into the dura mater of the anaesthetized guinea‐pig is described and the inability of 5‐ HT1B/1D agonists to achieve the same maximum as the endogenous agonist 5‐HT is explained by the additional presence of5‐HT2A receptors. Expand
Vasoconstriction in human isolated middle meningeal arteries: determining the contribution of 5-HT1B- and 5-HT1F-receptor activation.
TLDR
Experiments show that in human middle meningeal artery vasoconstriction to sumatriptan-like agents is 5-HT1B-receptor mediated with little if any contribution from 5- HT1F-receptors activation. Expand
...
1
2
3
4
...